Lenalidomide: Clinical Trials

370 trials of Lenalidomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

188 completed, 70 terminated, 41 active not recruiting, 24 recruiting. 370 Phase 1, 174 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1370Completed 188, Terminated 70, Active not recruiting 41, Recruiting 24, Unknown 22, Withdrawn 16, Not yet recruiting 7, Suspended 2
Phase 2174Completed 83, Terminated 26, Active not recruiting 19, Recruiting 16, Unknown 15, Withdrawn 10, Not yet recruiting 4, Suspended 1

Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide

Trials (filtered) newest first · largest first

All 370 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome
Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
Phase 1Not yet recruitingCity of Hope Medical Center142027-05-162026-11-09
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1Not yet recruitingIstituto Oncologico Veneto IRCCS142027-01-312026-11-03
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma
Phase 1 / Phase 2Not yet recruitingUniversitätsklinikum Hamburg-Eppendorf2202026-12-012026-05-20
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer
Phase 1RecruitingAndrew Hantel, MD902026-07-302026-11-02
HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len, Rituximab plus lenalidomide, Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len - Mantle Cell Lymphoma
Phase 1Not yet recruitingHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.402026-07-102026-07-13
Combining Latency Reversing Agents to Address the HIV Reservoir
Pyrimethamine (PYR), Lenalidomide, Topiramate (drug) - HIV (Human Immunodeficiency Virus), HIV -1 Infection
Phase 1 / Phase 2Not yet recruitingErasmus Medical Center302026-04-012026-02-03
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
JNJ-95566692, JNJ-87801493, loncastuximab tesirine - Lymphoma, Non-Hodgkin
Phase 1RecruitingJanssen Research & Development, LLC3402026-01-202026-11-03
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases. - Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor
Phase 1 / Phase 2Not yet recruitingThe Affiliated Hospital of Xuzhou Medical University302025-09-012025-08-21
Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.
PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders. - EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor
Phase 1 / Phase 2Not yet recruitingThe Affiliated Hospital of Xuzhou Medical University502025-09-012025-08-21
Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients
HuL001, Lenalidomide/Dexamethasone - Multiple Myeloma Refractory
Phase 1 / Phase 2RecruitingHuniLife Biotechnology, Inc.212025-08-182026-09-18
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma
Phase 1 / Phase 2RecruitingAbbVie6022025-06-302026-10-19
A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma
Ramantamig, Daratumumab, Pomalidomide - Multiple Myeloma, Smoldering Multiple Myeloma
Phase 1RecruitingJanssen Research & Development, LLC2802024-12-042026-11-17
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Phase 1RecruitingNational Cancer Institute (NCI)302024-05-202026-10-26
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Lenalidomide, Obinutuzumab Injection [Gazyva] - Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL)
Phase 1 / Phase 2RecruitingVitebsk Regional Clinical Cancer Centre242024-05-142026-08-13
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma
Phase 1Active not recruitingMayo Clinic162024-04-112026-08-17
Optimizing Reversal of HIV Latency With Combination Therapy
Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule - Hiv
Phase 1 / Phase 2UnknownErasmus Medical Center492024-04-012024-02-05
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Glofitamab, Obinutuzumab, Lenalidomide - Mantle Cell Lymphoma, MCL
Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center392024-01-082026-03-27
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Zanubrutinib, Lenalidomide, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1Active not recruitingInstitute of Hematology & Blood Diseases Hospital, China302024-01-012024-08-09
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Cevostamab, Lenalidomide, Tocilizumab - Multiple Myeloma
Phase 1 / Phase 2RecruitingHoffmann-La Roche2002023-11-142026-11-05
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Lenalidomide, Lenalidomide 25 MG Oral Capsule - Multiple Myeloma
Phase 1 / Phase 2RecruitingStarton Therapeutics, Inc242023-10-022026-08-24

Showing 20 of 370. Sign in to see all of them.

Conditions studied

Multiple Myeloma (128)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (43)  ·  Lymphoma, Large B-Cell, Diffuse (40)  ·  Lymphoma, Follicular (38)  ·  Lymphoma, Mantle-Cell (30)  ·  Recurrence (30)  ·  Lymphoma (28)  ·  Lymphoma, Non-Hodgkin (27)  ·  Lymphoma, B-Cell, Marginal Zone (25)  ·  Leukemia, Myeloid, Acute (19)  ·  Neoplasms, Plasma Cell (19)  ·  Myelodysplastic Syndromes (17)  ·  Lymphoma, B-Cell (16)  ·  Hodgkin Disease (14)  ·  Burkitt Lymphoma (12)

Sponsors

National Cancer Institute (NCI) (28)  ·  M.D. Anderson Cancer Center (23)  ·  Celgene (14)  ·  Mayo Clinic (13)  ·  City of Hope Medical Center (9)  ·  Massachusetts General Hospital (8)  ·  Memorial Sloan Kettering Cancer Center (7)  ·  Celgene Corporation (6)  ·  Janssen Research & Development, LLC (6)  ·  Case Comprehensive Cancer Center (5)  ·  Hoffmann-La Roche (5)  ·  Millennium Pharmaceuticals, Inc. (5)  ·  Arbeitsgemeinschaft medikamentoese Tumortherapie (4)  ·  Bristol-Myers Squibb (4)  ·  Dana-Farber Cancer Institute (4)

Countries

United States (266)  ·  France (33)  ·  Germany (30)  ·  Spain (29)  ·  Italy (22)  ·  Australia (18)  ·  United Kingdom (18)  ·  China (17)  ·  Canada (15)  ·  Netherlands (11)  ·  Austria (10)  ·  Belgium (10)  ·  Japan (10)  ·  South Korea (10)  ·  Israel (7)

Top investigators

James R Berenson, MD (3)  ·  Joseph M Tuscano (3)  ·  Noopur Raje, MD (3)  ·  Paul Richardson, MD (3)  ·  Robert Knight, MD (3)  ·  Shaji K. Kumar, M.D. (3)  ·  Christopher J Melani, M.D. (2)

Results publications

PMID 28314699, PMID 40802906, PMID 18056189, PMID 18824593, PMID 19011760, PMID 19182205, PMID 19451403, PMID 19965642, PMID 20385792, PMID 20508619, PMID 20724537, PMID 21149673, PMID 21596852, PMID 21816833, PMID 22033493, PMID 22422823, PMID 22451423, PMID 22517904, PMID 22546242, PMID 22640031, PMID 22665938, PMID 22677155, PMID 22915641, PMID 22936658, PMID 23085463, PMID 23100308, PMID 23242596, PMID 23417027, PMID 23447001, PMID 23592273, PMID 23676418, PMID 23756764, PMID 23834234, PMID 24004667, PMID 24014245, PMID 24351336, PMID 24562384, PMID 24761838, PMID 24914044, PMID 25052451, PMID 25082342, PMID 25135992, PMID 25210017, PMID 25456369, PMID 25824111, PMID 25837499, PMID 26058589, PMID 26284823, PMID 26331432, PMID 26337806

NIH funding

2023 (12), U01CA076576 (7), P30CA015083 (6), 2009 (5), 2015 (5), 2019 (5), P30CA016058 (5), P30CA043703 (4), UM1CA186712 (4), P30CA014599 (3), P30CA036727 (3), U10CA031946 (3), U10CA180821 (3), 2025 (2), N01CM00071 (2)